

Docket No.: 37998-237368

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Heinz Von Der Kammer

Art Unit: Not Yet Assigned

Application No: 10/596,627

Examiner: Not Yet Assigned

Confirmation No: 8551

Filed: June 19, 2006

Atty. Docket No: 37998-237368

Customer No:

For: DIAGNOSTIC AND THERAPEUTIC USE OF THE HUMAN HIF3ALPHA GENE AND PROTEINS FOR

NEURODEGENERATIVE DISEASES

26694 PATENT TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Application No.: 10/596,627 Docket No.: 37998-237368

In order to comply the duty of disclosure pursuant to 37 C.F.R. § 1.56, submitted herewith is a form listing the documents cited in the International Search Report of International Application No. PCT/EP2004/053573. The relevance of each document is indicated in the International Search Report.

Copies of the documents are not being provided since copies are furnished directly by WIPO under an exchange program between the PTO, the EPO and the JPO.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0261, under Order No. 37998-237368.

Dated: April 9, 2007

Respectfully submitted,

By Kavita B. Lepping

Kavita B. Lepping

Pagintration No. 54 26

Registration No.: 54,262 VENABLE LLP

P.O. Box 34385 Washington, DC 20043-9998 (202) 344-4000

(202) 344-8300 (Fax) Attorney/Agent For Applicant

KBL/cc

#834166

APR 09 100

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449/PTO Application Number 10/596,627 INFORMATION DISCLOSURE June 19, 2006 Filing Date STATEMENT BY APPLICANT First Named Inventor Heinz Von Der Kammer Art Unit Not Yet Assigned (Use as many sheets as necessary) Exeminer Name Not Yet Assigned Sheet of 1 Attorney Docket Number 37998-237368

U.S. PATENT DOCUMENTS					
Exeminer Initials*	Cite No.1	Document Number Number-Kind Coda ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pessages or Relevent Figures Appear

FOREIGN PATENT DOCUMENTS							
Exeminer Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Petentee or Applicant of Cited Document	Pagas, Columns, Linas, Where Ratevant Passagas or Ratevant Figures Appear	۲	
						Г	

EXAMINER: Initial if retarrons considered, whether or not clesion is in conformence with MPEP 800. Drew line through clasion if not in conformence and not considered, include copy of this from with next commission to payder. "Applicants unique clasion despetation makes (postpoid). "See Krids Closes of applicants, and the conformence and not considered applicants and the conformence and not considered applicants." Applicants are considered and the conformence and

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1				
/M.W	CA /	Yuichi Makino et at. "INHIBITORY PAS DOMAIN PROTEIN (IPAS) IS A HYPOXIA- INDUCIBLE SPLICING VARIANT OF HYPOXIA-INDUCIBLE FACTOR-3 ALPHA LOCUS," Journal of Biological Chemistry, American Society of Biological Chemists, Vol. 277, No. 36, September 9, 2002, pages 3246-532408.			
/M.W	CB /	Hara et al, "EXPRESSION AND CHARACTERIZATION OF HYPOXIA-INDUCIBLE FACTOR (HIF)-3 ALPHA IN HUMAN KIDNEY, SUPPRESSION OF HI-MEDIATED GENE EXPRESSION BY HIF-3 ALPHA," Biochemical and Biophysical Research Communications, Vol. 287, October 5, 2010, pages 908-913.			
/M.W	cc	Bazan et al, "HYPOXIA SIGNALING TO GENES SIGNIFICANCE IN ALZHEIMER'S DISEASE," Molecular Neurobiology, Vol. 26, No. 2/3, October 10, 2002, pages 283-298.			
/M.W	CD	Gu et al, "MOLECULAR CHARACTERIZATION AND CHROMOSOMAL LOCALIZATION OF A THRID ALPHA-CLASS HYPOXIA INDUCIBLE FACTOR SUBUNIT, HIF3 ALPHA," Gene Expression, Vol. 7, 1998, augus 205-213.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance end not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). 'Applicant is to place e check mark here if English language Translation is atteched. #834178

Examiner		Date	07/23/2008
Signature	/Michael Wilson/ (07/23/2008)	Considered	07/23/2000